Mezavant 1200 mg FC tablet
PDF Leaflet Revision Date: 16 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment and maintenance of remission in ulcerative colitis.
Dosage (summary)
Adults: 2.4 to 4.8 g once daily for induction; 2.4 g once daily for maintenance.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to potential risks.
Key Drug Interactions
- NSAIDs
- Azathioprine
- Warfarin
Contraindications
- Hypersensitivity to salicylates
- Severe renal impairment
- Severe hepatic impairment
Common side effects
- Colitis
- Abdominal pain
- Headache
- Diarrhoea
- Nausea
Counselling Points
- Swallow tablets whole
- Monitor for renal function
- Report unexplained bleeding or bruising
Serious warnings
- Renal impairment risk
- Severe cutaneous adverse reactions
- Cardiac hypersensitivity reactions
Important Disclaimer
The Mezavant 1200 mg FC tablet professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
